{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:23:36Z","timestamp":1776695016760,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.japh.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T11:23:13Z","timestamp":1659525793000},"page":"1925-1928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eosinophilic pustular folliculitis due to naltrexone: A case report"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-6225","authenticated-orcid":false,"given":"Sarah S.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Cernaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Tonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2022.07.007_bib1","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.japh.2022.07.007_bib4","author":"Volkow"},{"key":"10.1016\/j.japh.2022.07.007_bib5","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"10.1016\/j.japh.2022.07.007_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"American Psychiatric Association practice guideline for the pharmacological treatment of patient with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"2S Suppl 1","key":"10.1016\/j.japh.2022.07.007_bib7","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update [published correction appears in J Addict Med. 2020 May\/Jun;14(3):267]","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"7","key":"10.1016\/j.japh.2022.07.007_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.japh.2022.07.007_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145704004997","article-title":"Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials [published correction appears in Addiction. 2005;100(4):573. Magro, Angeles]","volume":"8","author":"Srisurapanont","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.japh.2022.07.007_bib10","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"7","key":"10.1016\/j.japh.2022.07.007_bib11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1176\/appi.ajp.2021.21050527","article-title":"Optimizing treatment for opioid use disorder","volume":"178","author":"Brady","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2022.07.007_bib13","first-page":"435","article-title":"Lithium and psoriasis: what primary care and family physicians should know","volume":"10","author":"Jafferany","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2022.07.007_bib14","first-page":"377","article-title":"Lithium-induced rash","volume":"8","author":"Sharma","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.japh.2022.07.007_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/pcn.12058","article-title":"Reversible skin rash in a bipolar disorder patient on first use of lithium","volume":"67","author":"Wang","year":"2013","journal-title":"Psychiatry Clin Neurosci"},{"issue":"10","key":"10.1016\/j.japh.2022.07.007_bib16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ccr3.3055","article-title":"Naltrexone-induced drug eruption","volume":"8","author":"Heck","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.japh.2022.07.007_bib17","series-title":"Adverse Cutaneous Drug Eruptions","author":"Kerl","year":"2012"},{"issue":"4","key":"10.1016\/j.japh.2022.07.007_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mcna.2021.04.001","article-title":"Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis)","volume":"105","author":"Owen","year":"2021","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.japh.2022.07.007_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11882-018-0778-6","article-title":"Severe cutaneous adverse drug reactions: presentation, risk factors, and management","volume":"18","author":"Mustafa","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/j.japh.2022.07.007_bib20","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.jaad.2011.10.023","article-title":"A\u00a0case of eosinophilic pustular folliculitis with response to infliximab","volume":"67","author":"Hasegawa","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.japh.2022.07.007_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/1346-8138.13359","article-title":"Eosinophilic pustular folliculitis: a proposal of diagnostic and therapeutic algorithms","volume":"43","author":"Nomura","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.japh.2022.07.007_bib22","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:42Z","timestamp":1761544302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1544319122002370"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.07.007","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilic pustular folliculitis due to naltrexone: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}